Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director · Chairman and CEO · 10% owner | July 09, 2019 | July 11, 2019 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · Chairman and CEO · 10% owner | January 12, 2023 | January 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promissory Note dated 9/14/17, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | Direct | 1 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. |
| Promissory Note dated 3/6/16, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | IndirectBy Hope International Hospice, Inc. | 1 |
Reported balance
After 2019-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown. |
Filing footnotes · ownership attribution and instrument terms
F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc.
F2: See footnote 1.
F3: Represents the outside date for completion of the proposed merger, unless extended by the parties.
F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction.
F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown.
Emmaus Life Sciences, Inc.
Report date January 12, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2028-01-11 | Direct | 0 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 7,500,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $3.13 | $626.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 12,101 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $3.12 | $624.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 11,901 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $3.11 | $1,555.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 11,701 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.09 | $309.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 11,201 Read SEC document |
| August 29, 2019 Filed Aug 30, 2019 18:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $3.06 | $1,836.00 |
DisclosureSEC source: 0001209191-19-047810 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 11,101 Read SEC document |
| August 29, 2019 Filed Sep 9, 2019 18:59 UTC Amendment | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 20,000 | $3.19 | $63,800.00 |
DisclosureSEC source: 0001209191-19-048868 · doc4a.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Soomi Niihara Disclosed balance after: 30,501 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.06 to $3.30, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $2.72 | $544.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 30 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,866 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $2.71 | $2,710.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 29 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,049,666 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,049 | $2.70 | $10,932.30 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 28 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,048,666 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $2.70 | $269.50 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 27 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,617 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 696 | $2.69 | $1,872.24 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 26 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,517 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,263 | $2.68 | $14,104.84 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 25 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,821 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 50 | $2.67 | $133.50 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 24 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,558 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,900 | $2.67 | $10,393.50 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 23 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,508 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 338 | $2.66 | $899.08 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 22 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,608 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $2.65 | $2,650.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 18 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,270 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,004 | $2.64 | $5,290.56 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 17 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,270 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,200 | $2.63 | $3,156.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 16 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,266 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $2.60 | $260.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 15 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,066 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,800 | $2.59 | $15,022.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 14 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,966 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $2.70 | $540.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 13 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,166 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 35 | $2.69 | $94.15 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 12 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057,966 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 800 | $2.68 | $2,144.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 11 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057,931 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $2.66 | $266.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 10 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057,131 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,100 | $2.65 | $2,915.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 9 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057,031 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 465 | $2.64 | $1,227.60 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 8 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,055,931 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $2.63 | $526.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 7 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,055,466 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 800 | $2.62 | $2,096.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 6 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,055,266 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 300 | $2.60 | $780.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,466 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 198 | $2.65 | $524.70 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,054,166 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,102 | $2.64 | $2,909.28 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,968 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,800 | $2.62 | $7,336.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,866 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $2.74 | $548.00 |
DisclosureSEC source: 0001209191-19-047559 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,066 F1 · ownership.direct: The shares shown and all other shares shown in this Report as owned directly include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| August 27, 2019 Filed Sep 9, 2019 17:48 UTC Amendment | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 25,900 | $2.65 | $68,635.00 |
DisclosureSEC source: 0001209191-19-048861 · doc4a.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,223,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.74, inclusive. Read SEC document |
| August 27, 2019 Filed Sep 9, 2019 17:48 UTC Amendment | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,100 | $2.63 | $10,783.00 |
DisclosureSEC source: 0001209191-19-048861 · doc4a.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,197,393 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.62 to $2.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| August 27, 2019 Filed Sep 9, 2019 17:46 UTC Amendment | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $2.65 | $10,600.00 |
DisclosureSEC source: 0001209191-19-048859 · doc4a.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,193,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.33 | $333.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 13 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,166 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.22 | $322.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 12 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,066 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 300 | $3.26 | $978.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 11 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,966 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 200 | $3.22 | $644.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 10 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,666 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,700 | $3.22 | $5,465.50 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 9 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,466 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 800 | $3.20 | $2,560.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 8 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,766 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.19 | $319.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 7 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,966 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $3.18 | $1,908.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 6 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,866 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 900 | $3.17 | $2,853.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 5 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,266 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 300 | $3.16 | $948.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,366 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 400 | $3.15 | $1,260.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,019,066 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 100 | $3.14 | $314.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,666 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 400 | $3.11 | $1,244.00 |
DisclosureSEC source: 0001209191-19-047558 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,566 F1 · ownership.direct: The shares shown and all other shares shown in this Report as owned directly include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| August 26, 2019 Filed Sep 9, 2019 17:46 UTC Amendment | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $3.19 | $19,140.00 |
DisclosureSEC source: 0001209191-19-048859 · doc4a.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,189,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.11 to $3.33, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.